KYTX Share Price Performance
US$8.17
4.63 (130.79%)
76.7% undervalued intrinsic discount
US$35.00
Fair Value
Price US$8.17
yygchong US$35.00
Fair ValueUS$35.00
Share Pricen/a
Seeking Alpha • Aug 13
Kyverna Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
KYTX Community Narratives
YY
Fair Value
·Fair Value US$35 76.7% undervalued intrinsic discount
Kyverna Bull Case
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Kyverna Bull Case
Kyverna is trying to bring a one-time immune-system “reset” treatment to people with autoimmune diseases, led by executives who have already taken similar therapies from lab to patients. It also has unusually strong partners and a long cash runway, but setbacks in trials or delays in key milestones could quickly change the story.Read more
YY
US$35
76.7% undervalued intrinsic discount
Fair Value
Profit Margin
19.56%
Future PE
N/A
Price in 2029
US$0
Trending Discussion
No trending discussion available.
Recently Updated Narratives
YY
Kyverna Bull Case
Fair Value: US$35 76.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kyverna Therapeutics, Inc. Key Details
About KYTX
- Founded
- 2018
- Employees
- 149
- CEO
- WebsiteView website
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
